Noradrenergic terminals regulate L-DOPA-derived dopamine extracellular levels in a region-dependent manner in Parkinsonian rats

CNS Neurosci Ther. 2014 Jul;20(7):671-8. doi: 10.1111/cns.12275. Epub 2014 Apr 28.

Abstract

Aims: Serotonin (5-HT) neurons mediate the ectopic release of dopamine (DA) induced by L-DOPA in the Parkinsonian brain. We hypothesized that the participation of noradrenalin transporters (NET) in the clearance of DA may account for the lower effect of L-DOPA in extrastriatal regions compared with the striatum.

Methods: Using a multisite intracerebral microdialysis approach, we tested the influence of the pharmacological blockade of NET and/or the destruction of noradrenalin (NE) fibers on DA and 5-HT release in the striatum, hippocampus (HIPP), substantia nigra pars reticulata (SNr) and prefrontal cortex (PFC) of 6-hydroxydopamine-lesioned rats.

Results: L-DOPA (12 mg/kg, i.p.) increased DA extracellular levels to a lesser extent in the SNr, PFC and HIPP compared with the striatum. The NET blockers desipramine (10 mg/kg, i.p.) and reboxetine (3 mg/kg, i.p.) potentiated L-DOPA effect in the PFC, SNr and HIPP but not in the striatum. The NE neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (50 mg/kg, i.p. 1 week before dialysis experiment) potentiated L-DOPA effect in the SNr and HIPP. 5-HT extracellular levels were enhanced only when L-DOPA was combined to NET blockers.

Conclusion: Noradrenalin neurons are indirectly involved in the mechanism of action of L-DOPA in part through the heterologous reuptake of DA in extrastriatal regions.

Keywords: Dopamine; Intracerebral microdialysis; Noradrenergic terminals; Serotonin; l-DOPA.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic Neurons / drug effects
  • Adrenergic Neurons / physiology*
  • Animals
  • Cerebral Cortex / drug effects
  • Cerebral Cortex / metabolism*
  • Corpus Striatum / drug effects
  • Corpus Striatum / metabolism*
  • Dopamine / metabolism*
  • Extracellular Fluid / metabolism
  • Levodopa / pharmacology*
  • Levodopa / therapeutic use
  • Male
  • Parkinsonian Disorders / drug therapy
  • Parkinsonian Disorders / metabolism*
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Levodopa
  • Dopamine